Payers comment on main drivers of health care utilization among patients with cold agglutinin disease. Neil Minkoff, MD: That gets to some of the questions; I want to start bringing our other ...

Clinicians offer their perspectives on establishing treatment goals for patients with cold agglutinin disease and describe how they measure treatment response. Neil Minkoff, MD: The question that ...

Please provide your email address to receive an email when new articles are posted on . Research presented at ASH Annual Meeting and Exposition provided an exciting update on many of the ...

DEAR DR. ROACH: What are the symptoms for cold agglutinin disease, and how is it diagnosed? — P.W. ANSWER: Cold agglutinin disease is a specific type of anemia where antibodies attack and destroy a ...

Sutimlimab is an IgG4 monoclonal antibody that inhibits the classical complement pathway. The Food and Drug Administration (FDA) has approved Enjaymo™ (sutimlimab-jome) to decrease the need for red ...

Dublin, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The "Cold Agglutinin Disease Market - A Global and Regional Analysis: Focus on Drug Class, Dosage Form, and Region - Analysis and Forecast, 2025-2035" has ...

CAMBRIDGE, Mass., Nov. 21, 2019 /PRNewswire/ -- Full data from the pivotal Phase 3 CARDINAL trial evaluating the safety and efficacy of sutimlimab in people with primary cold agglutinin disease (CAD) ...

In a recent case report published in the Journal of Clinical Laboratory Analysis, researchers presented two cases to highlight the impact of cold agglutinin syndrome (CAS) on clinical presentations in ...

Recordati is acquiring Sanofi’s Enjaymo, the only approved drug for the rare blood disorder cold agglutinin disease. Achieving sales milestones could bring the deal’s value to more than $1 billion. A ...

Cold agglutinin disease (CAD) is a rare subtype of autoimmune haemolytic anaemia (AIHA) where autoantibodies, predominantly of the IgM class, bind to red blood cells at reduced temperatures. This ...

DUBLIN--(BUSINESS WIRE)--The "Market Spotlight: Cold Agglutinin Disease" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers the Cold Agglutinin Disease ...

Recordati Rare Diseases Inc. today announced the presentation of real-world data that build upon the safety data of sutimlimab, an FDA-approved therapy for hemolysis in adults with cold agglutinin ...